Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential FACE Chemo and RIC for Refractory/Relapsed ALL
NCT02766868Phase 2Unknown
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Jan 2016
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, cytarabine, cyclophosphamide, etoposide and busulfan in acute lymphoblastic leukemia (ALL), sponsored by Shanghai Jiao Tong University School of Medicine. Primary endpoint: Disease-Free Survival at 2 years. Status: unknown.
02
Drugs
fludarabinecytarabinecyclophosphamideetoposidebusulfan
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02766868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02766868.